HCQS 200 mg contains hydroxychloroquine sulfate, a 4‑aminoquinoline compound with antimalarial and immunomodulatory properties. Hydroxychloroquine interferes with lysosomal activity and antigen presentation in immune cells, reduces cytokine production, and has antithrombotic effects. It is widely used for the prevention and treatment of malaria caused by Plasmodium vivax, P. malariae and sensitive P. falciparum, and for managing autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), and discoid lupus.
For malaria prophylaxis, HCQS is often taken at a dose of 400 mg once weekly, starting one week before exposure and continuing for four weeks after leaving the endemic area. For acute malaria treatment, the usual adult dose is 800 mg followed by 400 mg at 6, 24, and 48 hours. In autoimmune diseases, the typical maintenance dose is 200–400 mg daily, depending on body weight and clinical response. Take HCQS with food or milk to minimize gastrointestinal upset and swallow the tablets whole. Do not exceed the recommended dose; hydroxychloroquine accumulates in tissues and has a long half-life.
Common side effects include nausea, vomiting, diarrhea, abdominal cramps, loss of appetite, headache, dizziness, and skin rash. Prolonged use may cause retinopathy, vision disturbances, or pigmentary changes in the retina; regular ophthalmologic examinations are recommended during long-term therapy. Rare but serious adverse effects include cardiac arrhythmias, muscle weakness, hypoglycemia, or blood disorders. Hydroxychloroquine should be used with caution in patients with liver or kidney disease, psoriasis, porphyria, or glucose-6-phosphate dehydrogenase deficiency. Pregnant or breastfeeding women should discuss risks and benefits with their healthcare provider. Do not use HCQS concurrently with other antimalarial drugs containing quinine or chloroquine derivatives. For more information or to obtain this medication, visit: HCQS 200.
For malaria prophylaxis, HCQS is often taken at a dose of 400 mg once weekly, starting one week before exposure and continuing for four weeks after leaving the endemic area. For acute malaria treatment, the usual adult dose is 800 mg followed by 400 mg at 6, 24, and 48 hours. In autoimmune diseases, the typical maintenance dose is 200–400 mg daily, depending on body weight and clinical response. Take HCQS with food or milk to minimize gastrointestinal upset and swallow the tablets whole. Do not exceed the recommended dose; hydroxychloroquine accumulates in tissues and has a long half-life.
Common side effects include nausea, vomiting, diarrhea, abdominal cramps, loss of appetite, headache, dizziness, and skin rash. Prolonged use may cause retinopathy, vision disturbances, or pigmentary changes in the retina; regular ophthalmologic examinations are recommended during long-term therapy. Rare but serious adverse effects include cardiac arrhythmias, muscle weakness, hypoglycemia, or blood disorders. Hydroxychloroquine should be used with caution in patients with liver or kidney disease, psoriasis, porphyria, or glucose-6-phosphate dehydrogenase deficiency. Pregnant or breastfeeding women should discuss risks and benefits with their healthcare provider. Do not use HCQS concurrently with other antimalarial drugs containing quinine or chloroquine derivatives. For more information or to obtain this medication, visit: HCQS 200.
0